Australian Market Outlook - 30 August 2021

On Friday, Australian shares closed unchanged, dragged As part of the Morrison government's COVID-19 response down by retail conglomerate and rare earths and vaccine rollout, the Department of Health has spent at miner , as investors awaited Federal Reserve Chair least $36 million on outsourcing, including a $14.2 million Jerome Powell's speech for clues on the central bank's payment to consulting giant Accenture to build and tapering timeline. maintain a vaccination tracking system.

The benchmark S&P/ASX 200 index finished 0.04 percent had its worst day of the pandemic so far, with lower at 7,488.3 and fell for the second week in a row. 1324 new cases, the majority of which were in New South Wales, which reported 1218 community transmissions and Wesfarmers fell 2.8 percent after predicting a bleak start six deaths on Sunday. to fiscal 2022, despite a surprise A$2.3 billion ($1.66 billion) share buyback. More than $13 billion in JobKeeper payments were made to businesses that saw revenue increases, fueling Labor's The biggest losers on the index were technology stocks, claims that the wage subsidy was the biggest budget which fell 1.2 percent. Appen Ltd fell 6.1 percent, while waste in Australian history. NEXTDC fell 5.4 percent. Nutromics, a health-tracking technology company, has Gold stocks, on the other hand, rose, with Calidus closed a $5.7 million funding round, with Artesian investing Resources up 11% and Ora Banda Mining up 5.3 percent. for the third time.

Nuix's cratering, their stakes have become shadows of The 20-year-old, who was originally chosen for Team their former selves. Australia for the performance of his trial in the 100m butterfly, was a last-minute addition to the 400m freestyle Vawdrey's was valued at $4.3 million, down 68.6 percent by Australia to fill a third spot left open after his since the IPO, while Doyle's was valued at $2.3 million. countrymen, Alexander Tuckfield and world record holder Brenden Hall, had already qualified. Miners fell as copper prices in London fell. fell 6.6 percent, while fell 5.3 percent.

Top Gainers Top Losers

Company Last Price Change% Company Last Price Change%

Clinuvel Pharmaceuticals Ltd. $34.49 17.95% Pilbara Minerals Ltd. $2.07 -6.55%

Atlas Arteria $6.73 6.83% Appen Ltd. $10.20 -6.08%

Blackmores Ltd. $98.00 6.42% NEXTDC Ltd. $12.75 -5.42%

Nuix Ltd. $2.87 4.36% Orocobre Ltd. $8.31 -5.25%

Link Administration $4.33 -3.78% HUB24 Ltd. $31.60 3.57% Holdings Ltd. Australian Market Outlook - 30 August 2021

Disclaimer and General Advice Instructions:

This document is provided by Laverne Securities Pty Ltd T/as Laverne Investing the Corporate Authorized Representative No. CAR No. 001269781 of Laverne Capital Pty Ltd AFSL 482937. The Research Analyst who prepared this report/article hereby certifies that the views expressed in this document accurately reflect the analyst’s personal views about the Company and its financial products. The information provided in the Report/Article is provided by Morningstar and FactSet. Laverne Fund is not a fund manager, however, the portfolio and the document is for general advice only, prepared by the Analysts and Research team for our clients.

This report/article have Different Assumptions, Views, Analytical Method of the analyst with no guarantee of reliability and accuracy of the content. The Research Analyst has not been, is not, and will not be receiving direct or indirect compensation for expressing the specific recommendations or views in this report/article. Laverne Securities has its own Research methodology, with regards to the rating and is confirmed by the team for long term Strategic rating of the concerned security as an Investment for Portfolios with High Growth High Risk Profile. Individual Stock is Speculative and of High Risk in nature and strongly

This Document is provided for the Advisors, their Clients, and Financial Professionals for information only and should not be considered an offer or solicitation of an offer to buy or sell a particular security or financial product or instrument.

The information or services provided in this report/article may not be suitable for you and we strongly recommend taking the advice of your Financial Planner or Investment advisors. Laverne Investing will not treat the recipients as its customer by virtue of their receiving the report/article and should seek the advice of their consultant, prior to making any investment decision considering this report/article